托珠单抗联合阿替利珠单抗与立体定向放疗治疗复发胶质母细胞瘤:NRG Oncology-BN010 II期试验主要安全性及疗效分析
安全性导入期确定剂量水平3为最大耐受剂量,但研究未达到主要终点,客观缓解率为3.4%(95%CI 0.1%-17.8%),中位无进展生存期3.2个月,中位总生存期10.2个月。结论认为该联合方案安全且耐受良好,但未达到预设疗效目标。
要点
- 联合方案在复发胶质母细胞瘤中安全且耐受良好。
- 客观缓解率3.4%(95%CI 0.1%-17.8%),未达到主要终点。
- 中位无进展生存期3.2个月,中位总生存期10.2个月。
核心结论
- 托珠单抗、阿替利珠单抗联合FSRT在复发胶质母细胞瘤患者中安全且耐受良好,但未达到预设的疗效终点。
研究设计与样本
- 多中心、单臂、II期试验,含安全性导入期,随后采用Simon两阶段设计。
- 患者接受托珠单抗与阿替利珠单抗按28天周期给药,直至疾病进展、不可接受毒性或不超过2年。
- FSRT于全身治疗第1周期后3-7天开始,剂量为24 Gy分3次。
- 主要终点为按改良RANO标准评估的客观缓解率,评估窗口为入组后6个月。
主要发现
- 安全性导入期(n=12)确定剂量水平3(托珠单抗8 mg/kg、FSRT、阿替利珠单抗1680 mg)为最大耐受剂量。
- 研究未达到主要终点,客观缓解率为3.4%(95%CI 0.1%-17.8%)。
- 中位无进展生存期为3.2个月(95%CI 2.0-4.0),中位总生存期为10.2个月(95%CI 6.6-13.6)。
关键数值与推荐
- 两阶段设计用于区分真实缓解率不超过10%(无效假设)与不低于30%(备择假设)。
- 主要终点客观缓解率3.4%(95%CI 0.1%-17.8%)。
- 中位无进展生存期3.2个月(95%CI 2.0-4.0),中位总生存期10.2个月(95%CI 6.6-13.6)。
临床怎么用
- 该联合方案安全性可接受,但疗效未达预设目标,暂不支持在复发胶质母细胞瘤中常规使用。
- 结果可为后续免疫联合放疗研究的设计与终点设定提供参考。
局限性
- 单臂设计,无随机对照,疗效解释受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical data suggest that fractionated stereotactic radiation therapy (FSRT) may sensitize immunologically cold tumors to immune checkpoint inhibition by stimulating neoantigen release and that inhibition of interleukin-6 permits immunosuppressive tumor-associated macrophages to become immunostimulatory. This study aimed to test the safety and efficacy of the combination of tocilizumab (anti-IL6R), atezolizumab [anti-programmed death-ligand 1], and FSRT in patients with recurrent glioblastoma. METHODS AND MATERIALS: A multicenter, single-arm, phase 2 trial was conducted with a safety run-in phase followed by a Simon's 2-stage design. Patients received the combination of tocilizumab and atezolizumab administered on 28-day treatment cycles until disease progression, unacceptable toxicity, or for ≤2 years. FSRT (24 Gy in 3 fractions) was initiated 3-7 days following cycle 1 of systemic therapy. The primary endpoint was objective response rate by modified Response Assessment in Neuro-Oncology criteria. The window for assessment of the primary endpoint was 6 months from time of enrollment. The 2-stage design was used for the primary endpoint analysis to discriminate between true response rates of no more than 10% (null hypothesis) and ≥30% (alternative hypothesis). Secondary endpoints included the rates and severity of adverse events, progression-free survival, and overall survival. RESULTS: Forty-one patients were eligible and evaluable. The safety run-in (n = 12) established dose level 3 (combination of tocilizumab 8 mg/kg, FSRT, and atezolizumab 1680 mg) as the maximum-tolerated dose, which was subsequently evaluated in Simon's 2-stage design (n = 29). The study did not meet its primary endpoint (objective response rate 3.4%; 95% CI, 0.1%-17.8%). Median progression-free survival was 3.2 months (95% CI, 2.0-4.0), and median overall survival was 10.2 months (95% CI, 6.6-13.6). CONCLUSIONS: These findings suggest that the combination of tocilizumab, atezolizumab, and FSRT was safe and well tolerated in patients with recurrent glioblastoma but did not achieve the prespecified efficacy outcome.
引用
- Bagley SJ, Polley MC, Kotecha RR, et al. Tocilizumab, Atezolizumab, and Stereotactic Radiation Therapy in Recurrent Glioblastoma: Primary Analysis of Safety and Efficacy of a Phase 2 Trial, NRG Oncology-BN010. Int J Radiat Oncol Biol Phys. 2026. PMID: 42810412. doi:10.1016/j.ijrobp.2026.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。